Wnt/β-catenin signalling in adrenal physiology and tumour development

Molecular and Cellular Endocrinology

Volumn 351, Issue 1, 2012, Pages 87-95

  Berthon, Annabel ^a   Martinez, Antoine ^a   Bertherat, Jérôme ^b,c   Val, Pierre ^a  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b INSTITUT COCHIN   (France)

^c Hôpital Cochin ^*  (France)

Author keywords

Adenoma; Carcinoma; Physiopathology; Tumourigenesis; Wnt catenin

Indexed keywords

BETA CATENIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; DICKKOPF 1 PROTEIN; DICKKOPF 2 PROTEIN; DICKKOPF 3 PROTEIN; DICKKOPF 4 PROTEIN; GLYCOPROTEIN; METHIONINE; SOMATOMEDIN B; UNCLASSIFIED DRUG; WNT PROTEIN;

ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX DEVELOPMENT; ADRENAL CORTEX FUNCTION; BENIGN TUMOR; BIOACCUMULATION; CARCINOGENESIS; CELL RENEWAL; FAMILIAL COLON POLYPOSIS; GENE MUTATION; GENE OVEREXPRESSION; HOMEOSTASIS; HUMAN; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; MUTATIONAL ANALYSIS; NONHUMAN; ORGANOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TISSUE DIFFERENTIATION; TUMOR SUPPRESSOR GENE; ZONA GLOMERULOSA;

ACTIVE TRANSPORT, CELL NUCLEUS; ADRENAL GLAND NEOPLASMS; ANIMALS; BETA CATENIN; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; CYTOPLASM; HUMANS; MICE; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; TCF TRANSCRIPTION FACTORS; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84857118216     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.09.009     Document Type: Review

References (116)

1. Aberle H., Bauer A., Stappert J., Kispert A., Kemler R. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 1997, 16:3797-3804.
2. Abiven G., Coste J., Groussin L., Anract P., Tissier F., Legmann P., Dousset B., Bertagna X., Bertherat J. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J. Clin. Endocrinol. Metabol. 2006, 91:2650-2655.
3. Alexander G.L., Thompson G.B., Schwartz D.A. Primary aldosteronism in a patient with familial adenomatous polyposis, Mayo Clinic proceedings. Mayo Clinic 2000, 75:636-637.
4. Allolio B., Hahner S., Weismann D., Fassnacht M. Management of adrenocortical carcinoma. Clin. Endocrinol. 2004, 60:273-287.
5. Almeida M.Q., Muchow M., Boikos S., Bauer A.J., Griffin K.J., Tsang K.M., Cheadle C., Watkins T., Wen F., Starost M.F., Bossis I., Nesterova M., Stratakis C.A. Mouse Prkar1a haploinsufficiency leads to an increase in tumors in the Trp53+/- or Rb1+/- backgrounds and chemically induced skin papillomas by dysregulation of the cell cycle and Wnt signaling. Hum. Mol. Genet. 2010, 19:1387-1398.
6. Almeida M.Q., Stratakis C.A. Solid tumors associated with multiple endocrine neoplasias. Cancer Genet Cytogenet. 2010, 203:30-36.
7. Andrade Filho P.A., Letra A., Cramer A., Prasad J.L., Garlet G.P., Vieira A.R., Ferris R.L., Menezes R. Insights from studies with oral cleft genes suggest associations between WNT-pathway genes and risk of oral cancer. J. Dent. Res. 2011, 90:740-746.
8. Assie G., Louiset E., Sturm N., Rene-Corail F., Groussin L., Bertherat J., Thomas M., Lefebvre H., Feige J.J., Clauser E., Chabre O., Cherradi N. Systematic analysis of G protein-coupled receptor gene expression in adrenocorticotropin-independent macronodular adrenocortical hyperplasia identifies novel targets for pharmacological control of adrenal Cushing's syndrome. J. Clin. Endocrinol. Metab. 2010, 95:E253-E262.
9. Azevedo, M.F. and Stratakis, C.A., 2011. The transcriptome that mediates increased cAMP signaling in PRKAR1A defects and other settings, Endocr Pract. 1-19.
10. Balogh K., Patocs A., Hunyady L., Racz K. Menin dynamics and functional insight: take your partners. Molec. Cell. Endocrinol. 2010, 326:80-84.
11. Barrantes Idel B., Montero-Pedrazuela A., Guadano-Ferraz A., Obregon M.J., Martinez de Mena R., Gailus-Durner V., Fuchs H., Franz T.J., Kalaydjiev S., Klempt M., Holter S., Rathkolb B., Reinhard C., Morreale de Escobar G., Bernal J., Busch D.H., Wurst W., Wolf E., Schulz H., Shtrom S., Greiner E., Hrabe de Angelis M., Westphal H., Niehrs C. Generation and characterization of dickkopf3 mutant mice. Mol. Cell Biol. 2006, 26:2317-2326.
12. Beckers S., Abs R., Willems P.J., van der Auwera B., Kovacs K., Reznik M., Stevenaert A. Aldosterone-secreting adrenal adenoma as part of multiple endocrine neoplasia type 1 (MEN1): loss of heterozygosity for polymorphic chromosome 11 deoxyribonucleic acid markers, including the MEN1 locus, J. Clin. Endocrinol. Metab. 1992, 75:564-570.
13. Bernichtein S., Petretto E., Jamieson S., Goel A., Aitman T.J., Mangion J.M., Huhtaniemi I.T. Adrenal gland tumorigenesis after gonadectomy in mice is a complex genetic trait driven by epistatic loci. Endocrinology 2008, 149:651-661.
14. Bertherat J., Groussin L., Sandrini F., Matyakhina L., Bei T., Stergiopoulos S., Papageorgiou T., Bourdeau I., Kirschner L.S., Vincent-Dejean C., Perlemoine K., Gicquel C., Bertagna X., Stratakis C.A. Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. Cancer Res. 2003, 63:5308-5319.
15. Berthon A., Sahut-Barnola I., Lambert-Langlais S., de Joussineau C., Damon-Soubeyrand C., Louiset E., Taketo M.M., Tissier F., Bertherat J., Lefrancois-Martinez A.M., Martinez A., Val P. Constitutive {beta}-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Hum. Mol. Genet. 2010, 19:1561-1576.
16. Bertolino P., Tong W.M., Galendo D., Wang Z.Q., Zhang C.X. Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. Molec. Endocrinol. 2003, 17:1880-1892.
17. Beuschlein F., Reincke M., Koniger M., D'Orazio D., Dobbie Z., Rump L.C. Cortisol producing adrenal adenoma - a new manifestation of Gardner's syndrome. Endocr. Res. 2000, 26:783-790.
18. Bhanot P., Brink M., Samos C.H., Hsieh J.C., Wang Y., Macke J.P., Andrew D., Nathans J., Nusse R. A new member of the frizzled family from Drosophila functions as a Wingless receptor. Nature 1996, 382:225-230.
19. Bonnet S., Gaujoux S., Launay P., Baudry C., Chokri I., Ragazzon B., Libe R., Rene-Corail F., Audebourg A., Vacher-Lavenu M.C., Groussin L., Bertagna X., Dousset B., Bertherat J., Tissier F. Wnt/beta-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors. J. Clin. Endocrinol. Metab. 2011, 96:E419-E426.
20. Bossis I., Stratakis C.A. Minireview: PRKAR1A: normal and abnormal functions. Endocrinology 2004, 145:5452-5458.
21. Bourdeau I., Antonini S.R., Lacroix A., Kirschner L.S., Matyakhina L., Lorang D., Libutti S.K., Stratakis C.A. Gene array analysis of macronodular adrenal hyperplasia confirms clinical heterogeneity and identifies several candidate genes as molecular mediators. Oncogene 2004, 23:1575-1585.
22. Bourdeau I., Matyakhina L., Stergiopoulos S.G., Sandrini F., Boikos S., Stratakis C.A. 17q22-24 chromosomal losses and alterations of protein kinase a subunit expression and activity in adrenocorticotropin-independent macronodular adrenal hyperplasia. J. Clin. Endocrinol. Metab. 2006, 91:3626-3632.
23. Bovolenta P., Esteve P., Ruiz J.M., Cisneros E., Lopez-Rios J. Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. J. Cell Sci. 2008, 121:737-746.
24. Cao Y., Liu R., Jiang X., Lu J., Jiang J., Zhang C., Li X., Ning G. Nuclear-cytoplasmic shuttling of menin regulates nuclear translocation of {beta}-catenin. Mol. Cell Biol. 2009, 29:5477-5487.
25. Cavallo R.A., Cox R.T., Moline M.M., Roose J., Polevoy G.A., Clevers H., Peifer M., Bejsovec A. Drosophila Tcf and Groucho interact to repress Wingless signalling activity. Nature 1998, 395:604-608.
26. Chelaifa K., Bouzaidi K., Chouaib S., Azaiz O., Messaoud M.B., Slim R. Adrenal adenoma in a patient with Gardner's syndrome. A case report. Acta Radiol. 2003, 44:158-159.
27. Chen M., Hornsby P.J. Adenovirus-delivered DKK3/WNT4 and steroidogenesis in primary cultures of adrenocortical cells. Horm. Metab. Res. 2006, 38:549-555.
28. Christov M., Koren S., Yuan Q., Baron R., Lanske B. Genetic ablation of sfrp4 in mice does not affect serum phosphate homeostasis. Endocrinology 2011, 152:2031-2036.
29. Costa, S.C., Nascimento, L.S., Ferreira, F.J., Mattos, P.S., Camara-Lopes, L.H. and Ward, L.S., 2001. Lack of mutations of exon 2 of the MEN1 gene in endocrine and nonendocrine sporadic tumors, Brazilian journal of medical and biological research=Revista brasileira de pesquisas medicas e biologicas/Sociedade Brasileira de Biofisica [et al.]. 34, 86.
30. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378:785-789.
31. Dackiw A.P., Lee J.E., Gagel R.F., Evans D.B. Adrenal cortical carcinoma. World J. Surg. 2001, 25:914-926.
32. de Fraipont F., El Atifi M., Cherradi N., Le Moigne G., Defaye G., Houlgatte R., Bertherat J., Bertagna X., Plouin P.F., Baudin E., Berger F., Gicquel C., Chabre O., Feige J.J. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J. Clin. Endocrinol. Metab. 2005, 90:1819-1829.
33. de Reynies A., Assie G., Rickman D.S., Tissier F., Groussin L., Rene-Corail F., Dousset B., Bertagna X., Clauser E., Bertherat J. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J. Clin. Oncol. 2009, 27:1108-1115.
34. Devic A.B.M. Un cas de polypose adénomateuse: Generalitée à tout l'intestion. Arch. Mal. Appar. Dig. 1912, 6:278-289.
35. Ding Q., Xia W., Liu J.C., Yang J.Y., Lee D.F., Xia J., Bartholomeusz G., Li Y., Pan Y., Li Z., Bargou R.C., Qin J., Lai C.C., Tsai F.J., Tsai C.H., Hung M.C. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell. 2005, 19:159-170.
36. Ding V.M., Ling L., Natarajan S., Yap M.G., Cool S.M., Choo A.B. FGF-2 modulates Wnt signaling in undifferentiated hESC and iPS cells through activated PI3-K/GSK3beta signaling. J. Cell Physiol. 2010, 225:417-428.
37. Doghman M., Cazareth J., Lalli E. The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. J. Clin. Endocrinol. Metab. 2008, 93:3222-3225.
38. Eastman Q., Grosschedl R. Regulation of LEF-1/TCF transcription factors by Wnt and other signals. Curr. Opin. Biol. 1999, 11:233-240.
39. Fang D., Hawke D., Zheng Y., Xia Y., Meisenhelder J., Nika H., Mills G.B., Kobayashi R., Hunter T., Lu Z. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J. Biol. Chem. 2007, 282:11221-11229.
40. Fang X., Yu S.X., Lu Y., Bast R.C., Woodgett J.R., Mills G.B. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc. Natl. Acad. Sci. USA. 2000, 97:11960-11965.
41. Frame S., Cohen P. GSK3 takes centre stage more than 20years after its discovery. Biochem. J. 2001, 359:1-16.
42. Gaujoux S., Tissier F., Groussin L., Libe R., Ragazzon B., Launay P., Audebourg A., Dousset B., Bertagna X., Bertherat J. Wnt/beta-catenin and 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors. J. Clin. Endocrinol. Metab. 2008, 93:4135-4140.
43. Gaujoux S., Pinson S., Gimenez-Roqueplo A.P., Amar L., Ragazzon B., Launay P., Meatchi T., Libe R., Bertagna X., Audebourg A., Zucman-Rossi J., Tissier F., Bertherat J. Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers. Clin. Cancer Res. 2010, 16:5133-5141.
44. Gaujoux S., Grabar S., Fassnacht M., Ragazzon B., Launay P., Libe R., Chokri I., Audebourg A., Royer B., Sbiera S., Vacher-Lavenu M.C., Dousset B., Bertagna X., Allolio B., Bertherat J., Tissier F. Beta-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clin. Cancer Res. 2011, 17:328-336.
45. Gicquel C., Bertagna X., Gaston V., Coste J., Louvel A., Baudin E., Bertherat J., Chapuis Y., Duclos J.M., Schlumberger M., Plouin P.F., Luton J.P., Le Bouc Y. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res. 2001, 61:6762-6767.
46. Gicquel C., Raffin-Sanson M., Gaston V., Bertagna X., Plouin P.F., Schlumberger M., Louvel M., Luton J.P., Le Bouc Y. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J. Clin. Endocrinol. Metab. 1997, 82:2559-2565.
47. Giordano T.J., Thomas D.G., Kuick R., Lizyness M., Misek D.E., Smith A.L., Sanders D., Aljundi R.T., Gauger P.G., Thompson N.W., Taylor J.M.G., Hanash S. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am. J. Pathol. 2003, 162:521-531.
48. Groussin L., Kirschner L.S., Vincent-Dejean C., Perlemoine K., Jullian E., Delemer B., Zacharieva S., Pignatelli D., Carney J.A., Luton J.P., Bertagna X., Stratakis C.A., Bertherat J. Molecular analysis of the cyclic AMP-dependent protein kinase A (PKA) regulatory subunit 1A (PRKAR1A) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD. Am. J. Hum. Genet. 2002, 71:1433-1442.
49. Groussin L., Bertherat J., Gicquel C., le Bouc Y., Bertagna X. Insights into the molecular biology of adrenocortical tumors, Experimental and clinical endocrinology & diabetes: official journal, German Society of Endocrinology [and]. German Diabet. Assoc. 2007, 115:175-178.
50. Grumbach M.M., Biller B.M., Braunstein G.D., Campbell K.K., Carney J.A., Godley P.A., Harris E.L., Lee J.K., Oertel Y.C., Posner M.C., Schlechte J.A., Wieand H.S. Management of the clinically inapparent adrenal mass (" incidentaloma" ). Ann. Intern. Med. 2003, 138:424-429.
51. Hagen T., Vidal-Puig A. Characterisation of the phosphorylation of beta-catenin at the GSK-3 priming site Ser45. Biochem. Biophys. Res. Commun. 2002, 294:324-328.
52. Heikkila M., Peltoketo H., Leppaluoto J., Ilves M., Vuolteenaho O., Vainio S. Wnt-4 deficiency alters mouse adrenal cortex function, reducing aldosterone production. Endocrinology 2002, 143:4358-4365.
53. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 2003, 349:2042-2054.
54. Hino S., Tanji C., Nakayama K.I., Kikuchi A. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its ubiquitination. Mol. Cell Biol. 2005, 25:9063-9072.
55. Horvath A., Boikos S., Giatzakis C., Robinson-White A., Groussin L., Griffin K.J., Stein E., Levine E., Delimpasi G., Hsiao H.P., Keil M., Heyerdahl S., Matyakhina L., Libe R., Fratticci A., Kirschner L.S., Cramer K., Gaillard R.C., Bertagna X., Carney J.A., Bertherat J., Bossis I., Stratakis C.A. A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat. Genet. 2006, 38:794-800.
56. Horvath A., Mathyakina L., Vong Q., Baxendale V., Pang A.L., Chan W.Y., Stratakis C.A. Serial analysis of gene expression in adrenocortical hyperplasia caused by a germline PRKAR1A mutation. J. Clin. Endocrinol. Metab. 2006, 91:584-596.
57. Horvath A., Bossis I., Giatzakis C., Levine E., Weinberg F., Meoli E., Robinson-White A., Siegel J., Soni P., Groussin L., Matyakhina L., Verma S., Remmers E., Nesterova M., Carney J.A., Bertherat J., Stratakis C.A. Large deletions of the PRKAR1A gene in Carney complex. Clin. Cancer Res. 2008, 14:388-395.
58. Iliopoulos D., Bimpaki E.I., Nesterova M., Stratakis C.A. MicroRNA signature of primary pigmented nodular adrenocortical disease: clinical correlations and regulation of Wnt signaling. Cancer Res. 2009, 69:3278-3282.
59. Kartheuser A., Walon C., West S., Breukel C., Detry R., Gribomont A.C., Hamzehloei T., Hoang P., Maiter D., Pringot J., Rahier J., Khan P.M., Curtis A., Burn J., Fodde R., Verellen-Dumoulin C. Familial adenomatous polyposis associated with multiple adrenal adenomas in a patient with a rare 3' APC mutation. J. Med. Genetics 1999, 36:65-67.
60. Kikuchi A. Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Sci. 2003, 94:225-229.
61. Kim A.C., Reuter A.L., Zubair M., Else T., Serecky K., Bingham N.C., Lavery G.G., Parker K.L., Hammer G.D. Targeted disruption of beta-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex. Development 2008, 135:2593-2602.
62. King P., Paul A., Laufer E. Shh signaling regulates adrenocortical development and identifies progenitors of steroidogenic lineages. Proc. Natl. Acad. Sci. USA 2009, 106:21185-21190.
63. Kirschner L.S., Carney J.A., Pack S.D., Taymans S.E., Giatzakis C., Cho Y.S., Cho-Chung Y.S., Stratakis C.A. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat. Genet. 2000, 26:89-92.
64. Kuulasmaa T., Jaaskelainen J., Suppola S., Pietilainen T., Heikkila P., Aaltomaa S., Kosma V.M., Voutilainen R. WNT-4 mRNA expression in human adrenocortical tumors and cultured adrenal cells. Horm. Metab. Res. 2008, 40:668-673.
65. Lacroix A., Bourdeau I., Lampron A., Mazzuco T.L., Tremblay J., Hamet P. Aberrant G-protein coupled receptor expression in relation to adrenocortical overfunction. Clin. Endocrinol. (Oxf). 2010, 73:1-15.
66. Lako M., Strachan T., Bullen P., Wilson D.I., Robson S.C., Lindsay S. Isolation, characterisation and embryonic expression of WNT11, a gene which maps to 11q13.5 and has possible roles in the development of skeleton, kidney and lung. Gene 1998, 219:101-110.
67. Lee E.J., Jo M., Rho S.B., Park K., Yoo Y.N., Park J., Chae M., Zhang W., Lee J.H. Dkk3, downregulated in cervical cancer, functions as a negative regulator of beta-catenin. Int. J. Cancer 2009, 124:287-297.
68. Libe R., Bertherat J. Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. Eur. J. Endocrinol. 2005, 153:477-487.
69. Libe R., Fratticci A., Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr. Relat. Cancer 2007, 14:13-28.
70. Liu C., Li Y., Semenov M., Han C., Baeg G.H., Tan Y., Zhang Z., Lin X., He X. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002, 108:837-847.
71. Luton J.P., Cerdas S., Billaud L., Guilhaume B., Bertagna X., Laudat M.H., Louvel A., Chapuis Y., Blondeau P. Clinical features of adrenal carcinoma, prognostic factors. And the effect of mitotane therapy. N. Engl. J. Med. 1990, 322:1195-1201.
72. Mandel H., Shemer R., Borochowitz Z.U., Okopnik M., Knopf C., Indelman M., Drugan A., Tiosano D., Gershoni-Baruch R., Choder M., Sprecher E. SERKAL syndrome: an autosomal-recessive disorder caused by a loss-of-function mutation in WNT4. Am. J. Hum. Genet. 2008, 82:39-47.
73. Marchesa P., Fazio V.W., Church J.M., McGannon E. Adrenal masses in patients with familial adenomatous polyposis. Dis. Colon Rectum 1997, 40:1023-1028.
74. Maye P., Zheng J., Li L., Wu D. Multiple mechanisms for Wnt11-mediated repression of the canonical Wnt signaling pathway. J. Biol. Chem. 2004, 279:24659-24665.
75. Mizobuchi Y., Matsuzaki K., Kuwayama K., Kitazato K., Mure H., Kageji T., Nagahiro S. REIC/Dkk-3 induces cell death in human malignant glioma. Neurol. Oncol. 2008, 10:244-253.
76. Morali O.G., Delmas V., Moore R., Jeanney C., Thiery J.P., Larue L. IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene 2001, 20:4942-4950.
77. Nakamura R.E., Hunter D.D., Yi H., Brunken W.J., Hackam A.S. Identification of two novel activities of the Wnt signaling regulator Dickkopf 3 and characterization of its expression in the mouse retina. BMC Cell Biol. 2007, 8:52.
78. Nakamura R.E., Hackam A.S. Analysis of Dickkopf3 interactions with Wnt signaling receptors. Growth Factors 2010, 28:232-242.
79. Naylor E.W., Gardner E.J. Adrenal adenomas in a patient with Gardner's syndrome. Clin. Genet. 1981, 20:67-73.
80. Ng L., Libertino J.M. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J. Urol. 2003, 169:5-11.
81. Niehrs C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 2006, 25:7469-7481.
82. Orth D.N., Kovacs N.J. The adrenal cortex. Williams Text book of Endocrinology 1998, 517-664. WB Saunders Company, Philadelphia. ninth ed. J. Wilson (Ed.).
83. Ozuner G., Hull T.L. Familial desmoids in association with adrenal and ovarian masses and leiomyomas: report of three cases. Dis. Colon Rectum 1999, 42:529-532.
84. Painter T.A., Jagelman D.G. Adrenal adenomas and adrenal carcinomas in association with hereditary adenomatosis of the colon and rectum. Cancer 1985, 55:2001-2004.
85. Pines Corrales P.J., Gonzalez-Albarran O., Peralta M., Roa C., Anton T. Clinically inapparent adrenal mass in a patient with familial adenomatous polyposis. Horm. Res. 2006, 66:207-210.
86. Ragazzon B., Libe R., Gaujoux S., Assie G., Fratticci A., Launay P., Clauser E., Bertagna X., Tissier F., de Reynies A., Bertherat J. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res. 2010, 70:8276-8281.
87. Railo A., Nagy I.I., Kilpelainen P., Vainio S. Wnt-11 signaling leads to down-regulation of the Wnt/beta-catenin, JNK/AP-1 and NF-kappaB pathways and promotes viability in the CHO-K1 cells. Exp. Cell Res. 2008, 314:2389-2399.
88. Sahut-Barnola I., de Joussineau C., Val P., Lambert-Langlais S., Damon C., Lefrancois Martinez A.M., Pointud J.C., Marceau G., Sapin V., Tissier F., Ragazzon B., Bertherat J., Kirschner L.S., Stratakis C.A., Martinez A. Cushing's syndrome and foetal features resurgence in adrenal cortex-specific Prkar1a knockout mice. PloS Genet. 2010, 6:e1000980.
89. Sawyer E.J., Hanby A.M., Poulsom R., Jeffery R., Gillett C.E., Ellis I.O., Ellis P., Tomlinson I.P. Beta-catenin abnormalities and associated insulin-like growth factor overexpression are important in phyllodes tumours and fibroadenomas of the breast. J. Pathol. 2003, 200:627-632.
90. Schulte K.M., Heinze M., Mengel M., Simon D., Scheuring S., Kohrer K., Roher H.D. MEN I gene mutations in sporadic adrenal adenomas. Hum. Genet. 1999, 105:603-610.
91. Schulte K.M., Mengel M., Heinze M., Simon D., Scheuring S., Kohrer K., Roher H.D. Complete sequencing and messenger ribonucleic acid expression analysis of the MEN I gene in adrenal cancer. J. Clin. Endocrinol. Metab. 2000, 85:441-448.
92. Silva-Vargas V., Lo Celso C., Giangreco A., Ofstad T., Prowse D.M., Braun K.M., Watt F.M. Beta-catenin and Hedgehog signal strength can specify number and location of hair follicles in adult epidermis without recruitment of bulge stem cells. Dev. Cell. 2005, 9:121-131.
93. Smith T.G., Clark S.K., Katz D.E., Reznek R.H., Phillips R.K. Adrenal masses are associated with familial adenomatous polyposis. Dis. Colon Rectum 2000, 43:1739-1742.
94. Suwa T., Chen M., Hawks C.L., Hornsby P.J. Zonal expression of dickkopf-3 and components of the Wnt signalling pathways in the human adrenal cortex. J. Endocrinol. 2003, 178:149-158.
95. Suzuki H., Watkins D.N., Jair K.W., Schuebel K.E., Markowitz S.D., Chen W.D., Pretlow T.P., Yang B., Akiyama Y., Van Engeland M., Toyota M., Tokino T., Hinoda Y., Imai K., Herman J.G., Baylin S.B. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet. 2004, 36:417-422.
96. Suzuki K., Yamaguchi Y., Villacorte M., Mihara K., Akiyama M., Shimizu H., Taketo M.M., Nakagata N., Tsukiyama T., Yamaguchi T.P., Birchmeier W., Kato S., Yamada G. Embryonic hair follicle fate change by augmented beta-catenin through Shh and Bmp signaling. Development 2009, 136:367-372.
97. Tadjine M., Lampron A., Ouadi L., Bourdeau I. Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas. Clin. Endocrinol. 2008, 68:264-270.
98. Tadjine M., Lampron A., Ouadi L., Horvath A., Stratakis C.A., Bourdeau I. Detection of somatic beta-catenin mutations in primary pigmented nodular adrenocortical disease. Clin. Endocrinol. (Oxf.). 2008, 69:367-373.
99. Taurin S., Sandbo N., Qin Y., Browning D., Dulin N.O. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J. Biol. Chem. 2006, 281:9971-9976.
100. Taurin S., Hogarth K., Sandbo N., Yau D.M., Dulin N.O. Gbetagamma-mediated prostacyclin production and cAMP-dependent protein kinase activation by endothelin-1 promotes vascular smooth muscle cell hypertrophy through inhibition of glycogen synthase kinase-3. J. Biol. Chem. 2007, 282:19518-19525.
101. Taurin S., Sandbo N., Yau D.M., Sethakorn N., Dulin N.O. Phosphorylation of beta-catenin by PKA promotes ATP-induced proliferation of vascular smooth muscle cells. Am. J. Physiol. Cell Physiol. 2008, 294:C1169-C1174.
102. Tissier F., Cavard C., Groussin L., Perlemoine K., Fumey G., Hagnere A.M., Rene-Corail F., Jullian E., Gicquel C., Bertagna X., Vacher-Lavenu M.C., Perret C., Bertherat J. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 2005, 65:7622-7627.
103. Toyama T., Lee H.C., Koga H., Wands J.R., Kim M. Noncanonical Wnt11 inhibits hepatocellular carcinoma cell proliferation and migration. Mol. Cancer Res. 2010, 8:254-265.
104. Trevant B., Gaur T., Hussain S., Symons J., Komm B.S., Bodine P.V., Stein G.S., Lian J.B. Expression of secreted frizzled related protein 1, a Wnt antagonist, in brain, kidney, and skeleton is dispensable for normal embryonic development. J. Cell Physiol. 2008, 217:113-126.
105. Ugolini F., Adelaide J., Charafe-Jauffret E., Nguyen C., Jacquemier J., Jordan B., Birnbaum D., Pebusque M.J. Differential expression assay of chromosome arm 8p genes identifies Frizzled-related (FRP1/FRZB) and Fibroblast Growth Factor Receptor 1 (FGFR1) as candidate breast cancer genes. Oncogene 1999, 18:1903-1910.
106. Uysal-Onganer P., Kawano Y., Caro M., Walker M.M., Diez S., Darrington R.S., Waxman J., Kypta R.M. Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells. Mol. Cancer 2010, 9:55.
107. Verras M., Sun Z. Beta-catenin is involved in insulin-like growth factor 1-mediated transactivation of the androgen receptor. Mol. Endocrinol. 2005, 19:391-398.
108. Wajchenberg B.L., Albergaria Pereira M.A., Medonca B.B., Latronico A.C., Campos Carneiro P., Alves V.A., Zerbini M.C., Liberman B., Carlos Gomes G., Kirschner M.A. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000, 88:711-736.
109. Wakatsuki S., Sasano H., Matsui T., Nagashima K., Toyota T., Horii A. Adrenocortical tumor in a patient with familial adenomatous polyposis: a case associated with a complete inactivating mutation of the APC gene and unusual histological features. Hum. Pathol. 1998, 29:302-306.
110. Yamakita N., Murai T., Ito Y., Miura K., Ikeda T., Miyamoto K., Onami S., Yoshida T. Adrenocorticotropin-independent macronodular adrenocortical hyperplasia associated with multiple colon adenomas/carcinomas which showed a point mutation in the APC gene. Intern. Med. 1997, 36:536-542.
111. Yang S.H., Andl T., Grachtchouk V., Wang A., Liu J., Syu L.J., Ferris J., Wang T.S., Glick A.B., Millar S.E., Dlugosz A.A. Pathological responses to oncogenic Hedgehog signaling in skin are dependent on canonical Wnt/beta3-catenin signaling. Nat. Genet. 2008, 40:1130-1135.
112. Yang-Snyder J., Miller J.R., Brown J.D., Lai C.J., Moon R.T. A frizzled homolog functions in a vertebrate Wnt signaling pathway. Curr. Biol. CB. 1996, 6:1302-1306.
113. You A., Fokas E., Wang L.F., He H., Kleb B., Niederacher D., Engenhart-Cabillic R., An H.X. Expression of the Wnt antagonist DKK3 is frequently suppressed in sporadic epithelial ovarian cancer. J. Cancer Res. Clin. Oncol. 2011, 137:621-627.
114. Zhu H., Mazor M., Kawano Y., Walker M.M., Leung H.Y., Armstrong K., Waxman J., Kypta R.M. Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor. Cancer Res. 2004, 64:7918-7926.
115. Zi X., Guo Y., Simoneau A.R., Hope C., Xie J., Holcombe R.F., Hoang B.H. Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res. 2005, 65:9762-9770.
116. Zwermann O., Beuschlein F., Mora P., Weber G., Allolio B., Reincke M. Multiple endocrine neoplasia type 1 gene expression is normal in sporadic adrenocortical tumors. Eur. J. Endocr./Eur. Fed. Endocr. Soc. 2000, 142:689-695.